Woman Warns Of Brain Tumour Risks From Contraceptive Jab

A Shock Diagnosis And A Call For Action

Frances Connolly, a 48-year-old mother from Forfar in Angus, discovered she had a meningioma brain tumour under unexpected circumstances. The diagnosis came in 2018 during a C-section delivery of her youngest son. At the time, she had shown no symptoms of the growth. The mass was only identified via an MRI scan after she had contracted sepsis, revealing that the tumour had been growing undetected inside her skull.

Prior to her pregnancy, Ms. Connolly had used the Depo-Provera birth control injection for 15 years. Following her diagnosis, she has become a vocal advocate for women’s health, warning that those using the drug long-term could be living as “ticking time bombs.” She describes the experience as chilling, noting that because tell-tale signs may be absent, tumours can go completely undetected until they reach a critical stage.

The Impact Of Long-Term Use

Since the diagnosis, Ms. Connolly has faced life-altering challenges. She reports suffering from serious fatigue and memory loss, stating that she sometimes struggles to recall special memories. After undergoing surgery to remove the tumour, she describes herself as a different person, viewing the diagnosis as a devastating blow to her quality of life. She believes that the surgery changed her fundamentally, leaving her to cope with a new reality.

Ms. Connolly argues that women are often drawn to the injection because of its convenience but are not sufficiently warned about the potential risks. She believes that if routine screenings cannot be provided to monitor users, the drug should be removed from the market entirely. Her primary goal is to ensure that other women do not face the same silent growth of tumours in their heads, as she fears hundreds of others may be in the same position without knowing it.

Legal Battles And Medical Evidence

Ms. Connolly has joined a group of approximately 150 victims in Scotland who are fighting for better regulation of the medication in the UK. Legal representatives for the women have described the situation as deeply upsetting, highlighting that many users were prescribed the drug for years without warnings about potential side effects. There are calls for political leadership from both Holyrood and Westminster to institute a full UK-wide public inquiry to prevent further illnesses and help current victims learn lessons from these cases.

The link between Depo-Provera and meningiomas was established in 2014. Research published in the British Medical Journal found that women using the drug were five times more likely to be diagnosed with these specific tumours compared to women who had never used the contraceptive. This evidence has fueled legal actions, with around 5,000 women currently suing the manufacturer in the US, while group actions are expanding across England and the rest of the UK.

Regulatory Responses And Guidelines

In response to the growing concerns, Scotland’s Chief Pharmaceutical Officer recently instructed general practitioners to warn women about the risk of tumour side effects. Healthcare providers have been told to review prescriptions every two years and to remain vigilant for signs of suspected tumours. However, advocates like Ms. Connolly argue these guidelines are insufficient, insisting that proactive annual MRI screenings are the only way to prevent disability or death.

Health spokespeople have emphasized that the Scottish Government must prioritize proactive screening rather than leaving detection to chance. They argue that women’s health issues cannot be ignored or left to worsen. Meanwhile, the MHRA Chief Safety Officer stated that patient safety remains a top priority and that the safety of medroxyprogesterone acetate is under continual review. The MHRA maintains that for most people, the benefits of the drug outweigh the risks, though they advise anyone with concerns to consult a healthcare provider.

A spokesperson for the manufacturer, Pfizer, stated that the company conducts rigorous and continuous monitoring of its medicines and works in collaboration with global health authorities to assess reported adverse events.